Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.10.24 | Celldex Therapeutics' Barzolvolimab Meets Phase 2 Study Endpoints For Chronic Inducible Urticaria | 653 | AFX News | WASHINGTON (dpa-AFX) - Celldex Therapeutics Inc. (CLDX) announced that barzolvolimab met all primary and secondary endpoints with high statistical significance in a positive Phase 2 study targeting... ► Artikel lesen | |
27.10.24 | Novartis Announces Promising 12-Month Results For Fabhalta In C3 Glomerulopathy | 779 | AFX News | BASEL (dpa-AFX) - Novartis (NVS) presented 12-month data from the Phase III APPEAR-C3G study at the American Society of Nephrology or ASN Kidney Week 2024. The results showed that patients with... ► Artikel lesen | |
27.10.24 | Biogen's Phase 2 Study Shows Promising Results For Felzartamab In IgA Nephropathy | 681 | AFX News | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy... ► Artikel lesen |
Suchbegriffe der letzen 24 h | Anzahl |
---|---|
RHEINMETALL | 4.145 |
RENK GROUP | 3.417 |
NVIDIA | 1.929 |
TUI | 1.847 |
THYSSENKRUPP | 1.791 |
BYD | 1.474 |
SUPER MICRO COMPUTER | 1.463 |
HENSOLDT | 1.358 |
BAYER | 1.266 |
FORMYCON | 1.186 |
TESLA | 1.167 |
EVOTEC | 1.166 |
INTEL | 1.109 |
NEL | 940 |
PUMA | 889 |
BASF | 851 |
ALIBABA | 817 |
COMMERZBANK | 816 |
NOVO NORDISK | 798 |
DEUTSCHE BANK | 769 |
VOLKSWAGEN | 728 |
MERCEDES-BENZ | 666 |
SIEMENS ENERGY | 634 |
DEUTSCHE TELEKOM | 612 |
PALANTIR TECHNOLOGIES | 590 |